GLP1R and Hepatic steatosis: The current preclinical evidence shows that GLP-1 analogs and DPP-4 inhibitors can improve hepatic steatosis independent of weight loss but is controversial whether the pancreatic-type GLP-1 receptor is present or responsible for conferring the GLP-1 signal in the hepatocyte [66].